This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): ganciclovir opthalmic gel 0.15%, Virgan (EU)
Description: ZIRGAN contains 0.15% of ganciclovir in a sterile preserved topical ophthalmic gel. Ganciclovir is a guanosine derivative that, upon phosphorylation, inhibits DNA replication by herpes simplex viruses (HSV). Ganciclovir is transformed by viral and cellular thymidine kinases (TK) to ganciclovir triphosphate, which works as an antiviral agent by inhibiting the synthesis of viral DNA in 2 ways: competitive inhibition of viral DNA-polymerase and direct incorporation into viral primer strand DNA, resulting in DNA chain termination and prevention of replication.
Deal Structure: In January 2007, Sirion Therapeutics acquired a license for Zirgan from Laboratoires Thea for U.S. marketing rights.
In June 2010, Bausch + Lomb, acquired the assets and U.S. rights for Zirgan (ganciclovir ophthalmic gel 0.15%) from Sirion Therapeutics.
In May 2013, Valeant and Bausch + Lomb announced that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash.
In August 2013, Valeant announced it has completed the acquisition of Bausch + Lomb.
Partners: Sirion Holdings, Inc. Laboratorios Théa
Pink Sheet September 2009 Approvals
Additional information available to subscribers only: